Autoimmune-autoinflammatory rheumatoid arthritis overlaps: a rare but potentially important subgroup of diseases by Savic, S et al.
  1Savic S, et al. RMD Open 2017;3:e000550. doi:10.1136/rmdopen-2017-000550
AbstrAct
At the population level, rheumatoid arthritis (RA) is 
generally viewed as autoimmune in nature with a small 
subgroup of cases having a palindromic form or systemic 
autoinflammatory disorder (SAID) phenotype. Herein, 
we describe resistant cases of classical autoantibody 
associated RA that had clinical, genetic and therapeutic 
responses indicative of coexistent autoinflammatory 
disease. Five patients with clinically overlapping features 
between RA and SAID including polysynovitis and 
autoantibody/shared epitope positivity, and who had 
abrupt severe self-limiting attacks including fevers and 
serositis, are described. Mutations or single nucleotide 
polymorphisms in recognised autoinflammatory pathways 
were evident. Generally, these cases responded poorly 
to conventional Disease-modifying anti-rheumatic drugs 
(DMARD) treatment with some excellent responses to 
colchicine or interleukin 1 pathway blockade. A subgroup 
of RA cases have a mixed autoimmune-autoinflammatory 
phenotype and genotype with therapeutic implications.
IntroductIon
Rheumatoid arthritis (RA) is genetically, 
phenotypically and molecularly heteroge-
neous. Most cases have an autoimmune 
phenotype as indicated by the major histocom-
patibility complex Class 2 (MHC-II) associa-
tion, shared autoantibodies and responses to 
B cell depletion and co-stimulatory blockade 
therapies. However, there is growing evidence 
that innate immunity plays an important 
role in the pathogenesis of this disorder.1 
We and others have also observed that some 
RA cases clinically resemble patients with 
so-called systemic autoinflammatory disor-
ders (SAIDs),2 which would support this idea.
Broadly speaking SAIDs are diseases of the 
innate immunity caused by the mutations in 
genes including TNFRSF1A, NLRP3, MEFV 
and NOD2, which control the release of the 
proinflammatory cytokines, mainly inter-
leukin (IL)-1ß, and IL-6 and Tumor necrosis 
factor (TNF).3 Typically, the patients experi-
ence abrupt systemic inflammatory attacks 
characterised by fever, prominent joint 
swelling, erythema and a raised C-Reactive 
protein (CRP). Furthermore, patients with 
SAID respond to therapies such as colchi-
cine and anti-IL-1 biologics, which target the 
innate immune system. We present a series 
of five patients who have overlapping clinical 
features of RA and SAID.
MaterIals and Methods
For detailed information regarding patients’ 
clinical assessment, and methods used for 
genetic and cytokine studies, please see 
online supplementary file 1.
case 1
A 54-year-old man presented at the age of 
35 years with episodic night sweats, fever, 
erythematous skin rash and bilateral symmet-
rical synovitis suggestive of RA (figure 1). 
Investigations showed elevated CRP and nega-
tive rheumatoid factor (RF), and skin biopsy 
had features in keeping with urticarial vascu-
litis. Over the next decade, he continued 
to suffer with episodic skin rashes and 
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Key messages
 ► A subgroup of rheumatoid arthritis (RA) cases 
can have a mixed autoimmune-autoinflammatory 
overlapping clinical phenotype which has 
implications for choice of appropriate therapy.
 ► This points to innate immunity or autoinflammatory 
mechanisms as underpinning flare or relapse in 
some autoantibody positive RA cases.
 ► These findings point to the marked genetic 
heterogeneity in RA cases that is thus far poorly 
recognised.
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Figure 1 Proinflammatory cytokine production from whole 
blood assay (case 1) in response to lipopolysaccharide (LPS) 
and after LPS/IL-10 combination (A,B,C). Picture of inflamed 
skin/joints, case 1 (D).
synovitis associated with systemic inflammation. He failed 
numerous empirical treatments including combinations 
of methotrexate and etanercept and methotrexate and 
tocilizumab (table 1). At the age of 47 years he was 
found to have a known pathogenic missense variant in 
the NLRP3 gene (p.Arg325Trp) consistent with diagnosis 
of cryopyrin associated periodic syndrome (CAPS).4 His 
lipopolysaccharide (LPS)-stimulated Peripheral mono-
nuclear cells (PBMC) produced considerably higher 
levels of IL-1β compared with healthy controls. (figure 1). 
Anakinra was initiated (IL-1RA) in combination with 
methotrexate resulting in complete disease remission 
and normalisation of his CRP. As his methotrexate was 
withdrawn he had a major relapse of synovitis and devel-
oped clinical features of RA in association with anticit-
rullinated peptide antibodies (ACPAs) and RF positivity. 
His methotrexate was re-started and he again achieved 
clinical remission, but remains ACPA-positive.
case 2
A 55-year-old woman presented at the age of 53 years with 
a 6 -month history of flitting palindromic arthropathy and 
raised inflammatory markers. Her symptoms would come 
on very abruptly and were accompanied by overlying soft 
tissue swelling and skin erythema. She also had a hospital 
admission for possible aseptic meningitis and later devel-
oped a blistering rash (negative antibullous Ab) and 
bilateral scleritis. She was found to be RF-positive and 
ACPA-positive. Genetic test revealed a compound hete-
rozygote mutation in the MEFV gene c.289 C>T (Q97*) 
and c.605G>A (R202Q). Her PBMCs showed increased 
levels of IL-6 production following LPS stimulation, 
compared with healthy control. This response was poorly 
downregulated by IL-10 (figure 2). The patient had a 
modest benefit from colchicine but was unable to tolerate 
more than 500 µg/day. She responded well to a course of 
prednisolone and methotrexate, but remains dependent 
on low-dose prednisolone (7.5 mg).
case 3
A 50-year-old man presented at the age of 49 years with a 
12 -month history of synovitis, pleurisy, fever and pericar-
ditis. He was initially diagnosed with polyarticular gout 
since the attacks of swelling around his foot were abrupt 
and associated with severe erythema. However subse-
quent investigations (table 1) were negative for gout 
and he was found to have high-titre ACPA and RF and a 
variant in NOD2 (c.2722G>C, p.Gly908Arg). He was orig-
inally managed with subcutaneous methotrexate but this 
was discontinued due to infective complications. Despite 
a reasonable initial response to colchicine and predniso-
lone, sulfasalazine was added to this combination as he 
continued to suffer from intermittent episodes of joint 
swelling associated with persistently raised CRP. The addi-
tion of sulfasalazine did not result in complete resolution 
of the attacks.
case 4
A 42-year-old man at the age of 40 years developed severe 
right hip pain, with elevated CRP and neutrophilia. An 
aspirate was sterile and an MRI showed inflammation of 
the joint. He responded readily to diclofenac and antibi-
otic therapy, with complete resolution of his symptoms 
within 4 days. He had a similar presentation 5 months 
later in the other hip. The investigations showed both RF 
positivity and ACPA positivity and a polymorphism within 
the NOD2 gene c.2104 C>T (pArg702Trp). He bene-
fited from an intramuscular corticosteroid pulse and was 
started on methotrexate, however the latter was discon-
tinued because of tinnitus. Over the coming months, he 
developed clinical features of an asymmetrical polyar-
thritis which included episodes of marked knee swelling 
and an erythematous rash over affected joints. He was 
commenced on colchicine 500 µg twice daily resulting in 
complete resolution of his symptoms.
case 5
A 60-year-old woman presented initially at the age of 43 
years with metacarpophalangeal (MCP) joint swelling 
and a knee effusion. The synovial fluid analysis was 
negative. Over the following years she continued to 
suffer from fleeting episodes of severe MCP and knee 
joint swelling resulting in frequent attendance to acute 
medical services. There was never any documented fever 
or evidence of septic arthritis. Her clinical picture resem-
bled RA with some atypical features. She was RF-positive 
but ACPA-negative and had elevated CRP during attacks. 
The genetic tests for SAID were negative. She received 
multiple treatments for presumed RA (table 1). However, 
the patient continued to experience acute, short-lived 
but disabling attacks of synovitis. She responded rapidly 
to colchicine with an almost instant cessation of her 
symptoms and stopped Disease-modifying anti-rheumatic 
drugs (DMARD) triple therapy.
group.bmj.com on November 6, 2017 - Published by http://rmdopen.bmj.com/Downloaded from 
3Savic S, et al. RMD Open 2017;3:e000550. doi:10.1136/rmdopen-2017-000550
Autoinflammatory disorders
Ta
b
le
 1
 
S
um
m
ar
y 
of
 c
lin
ic
al
 fe
at
ur
es
, i
nv
es
tig
at
io
ns
 a
nd
 t
re
at
m
en
ts
P
1
P
2
P
3
P
4
FD
FF
S
D
A
 P
5
D
em
og
ra
p
hi
cs
S
ex
M
F
M
M
F
C
ur
re
nt
 a
ge
55
56
50
42
 y
ea
rs
60
 y
ea
rs
A
ge
 a
t 
fir
st
 
p
re
se
nt
at
io
n
35
53
A
ge
 4
0 
ye
ar
s—
R
A
A
ge
 4
9 
ye
ar
s—
au
to
in
fla
m
m
at
or
y 
fe
at
ur
es
40
 y
ea
rs
43
 y
ea
rs
A
ut
oi
m
m
un
e 
sc
re
en
A
N
A
−
−
−
−
−
A
C
PA
+
+
+
+
−
R
F
+
+
−
+
P
os
iti
ve
 in
iti
al
ly
A
N
C
A
-
−
P
os
iti
ve
 o
n 
on
e 
oc
ca
si
on
, 
an
tim
ye
lo
p
er
ox
id
as
e 
an
tib
od
ie
s 
d
et
ec
te
d
. 
R
ep
ea
te
d
 A
N
C
A
 h
av
e 
b
ee
n 
ne
ga
tiv
e 
on
 s
ev
er
al
 
oc
ca
si
on
s.
−
−
G
en
et
ic
 t
es
t
S
ha
re
d
 e
p
ito
p
e
D
R
B
1*
04
:0
1 
an
d
 *
04
:0
8
D
R
B
1*
01
:0
1 
ho
m
oz
yg
ou
s
D
R
B
1*
04
:0
1 
an
d
 *
04
:0
4
D
R
B
1*
04
:0
1 
ho
m
oz
yg
ou
s
D
R
B
1*
04
:0
1 
an
d
 *
04
:0
8
N
LR
P
3
c9
73
C
>
T 
(p
A
rg
32
5T
rp
)
N
il
ni
l
N
il
N
il
M
E
FV
N
il
c2
89
C
>
T 
(p
G
ln
97
*)
, 
c6
05
G
>
A
 (p
A
rg
20
2G
ln
)
ni
l
N
il
N
il
N
O
D
2
N
il
N
il
c2
72
2G
>
C
 (p
G
ly
90
8A
rg
)
c2
10
4 
C
>
T 
(p
A
rg
70
2T
rp
)
N
il
O
th
er
 
in
ve
st
ig
at
io
ns
H
ig
he
st
 C
R
P
 in
 
th
e 
ab
se
nc
e 
of
 
in
fe
ct
io
n 
(m
g/
l)
15
0
42
61
20
0
70
N
eu
tr
op
hi
lia
In
te
rm
itt
en
tly
, d
ur
in
g 
un
co
nt
ro
lle
d
 d
is
ea
se
 
ep
is
od
es
In
te
rm
itt
en
tly
Ye
s,
 p
er
si
st
en
tly
 r
ai
se
d
Ye
s,
 d
ur
in
g 
ac
ut
e 
fla
re
s
N
o
X
-r
ay
M
ild
 e
ro
si
ve
 c
ha
ng
es
D
eg
en
er
at
iv
e 
ch
an
ge
s 
on
ly
N
or
m
al
, M
R
I s
ho
w
ed
 
in
fla
m
m
at
io
n
D
eg
en
er
at
iv
e 
ch
an
ge
s,
 
b
ut
 n
o 
er
os
io
ns
S
ki
n 
b
io
p
sy
C
on
fir
m
ed
 a
s 
lic
he
n 
p
la
nu
s
U
lc
er
at
ed
 e
p
id
er
m
is
 w
ith
 
co
lle
ct
io
ns
 o
f n
eu
tr
op
hi
ls
 
on
 t
he
 s
ur
fa
ce
N
ot
 d
on
e
N
ot
 d
on
e
N
ot
 d
on
e
C
on
tin
ue
d
group.bmj.com on November 6, 2017 - Published by http://rmdopen.bmj.com/Downloaded from 
4 Savic S, et al. RMD Open 2017;3:e000550. doi:10.1136/rmdopen-2017-000550
RMD Open
P
1
P
2
P
3
P
4
FD
FF
S
D
A
 P
5
C
lin
ic
al
 fe
at
ur
es
Fe
ve
rs
+
+
+
−
−
S
ki
n 
ra
sh
+
, c
on
fir
m
ed
 a
s 
lic
he
n 
p
la
nu
s 
on
 b
io
p
sy
+
P
ro
fo
un
d
 e
ry
th
em
a 
at
 s
ite
s 
of
 s
yn
ov
iti
s
+
E
ry
th
em
a 
at
 s
ite
s 
of
 
sy
no
vi
tis
A
rt
hr
iti
s
+
+
+
+
+
S
yn
ov
iti
s
+
+
+
+
+
S
er
os
iti
s
-
P
os
si
b
le
—
on
e 
ho
sp
ita
l 
ep
is
od
e 
w
ith
 s
ym
p
to
m
s 
co
ns
is
te
nt
 w
ith
 
m
en
in
gi
sm
. A
 lu
m
b
ar
 
p
un
ct
ur
e 
as
p
ira
te
 w
as
 
st
er
ile
.
+
 p
er
ic
ar
d
iti
s,
 p
le
ur
iti
s 
(c
on
fir
m
ed
 w
ith
 
ec
ho
ca
rd
io
gr
am
 a
nd
 C
T)
−
−
Tr
ea
tm
en
t
C
or
tic
os
te
ro
id
s
Ye
s,
 g
oo
d
 r
es
p
on
se
Ye
s,
 g
oo
d
 r
es
p
on
se
Ye
s—
go
od
 r
es
p
on
se
Ye
s—
go
od
 r
es
p
on
se
Ye
s—
p
ar
tia
l r
es
p
on
se
C
ol
ch
ic
in
e
Ye
s,
 n
o 
re
sp
on
se
Ye
s,
 p
ar
tia
l r
es
p
on
se
 
st
op
p
ed
 d
ue
 t
o 
si
d
e 
ef
fe
ct
s
Ye
s—
go
od
 r
es
p
on
se
Ye
s—
ex
ce
lle
nt
 r
es
p
on
se
 
w
ith
 n
or
m
al
is
at
io
n 
of
 
C
R
P
Ye
s—
ex
ce
lle
nt
 c
lin
ic
al
 
re
sp
on
se
M
et
ho
tr
ex
at
e
Ye
s,
 p
ar
tia
l r
es
p
on
se
, 
d
ev
el
op
ed
 R
A
-l
ik
e 
fla
re
 
w
he
n 
st
op
p
ed
 d
ue
 t
o 
in
to
le
ra
nc
e
Ye
s,
 g
oo
d
 r
es
p
on
se
Ye
s—
p
ar
tia
l, 
st
op
p
ed
 d
ue
 t
o 
in
to
le
ra
nc
e
Ye
s—
p
ar
tia
l r
es
p
on
se
Ye
s—
p
ar
tia
l r
es
p
on
se
an
ti-
TN
F
Ye
s,
 r
es
p
on
se
 in
iti
al
ly
, b
ut
 
se
co
nd
ar
y 
no
n-
re
sp
on
se
 
to
 e
ta
na
rc
ep
t
N
o
N
o
N
o
N
o
an
ti-
IL
-6
Ye
s,
 p
ar
tia
l r
es
p
on
se
, 
no
rm
al
is
at
io
n 
of
 C
R
P
 o
nl
y
N
o
N
o
N
o
N
o
an
ti-
IL
-1
C
om
p
le
te
 r
es
p
on
se
 
to
 a
na
ki
nr
a,
 a
lth
ou
gh
 n
on
-
re
sp
on
se
 t
o 
ca
na
ki
nu
m
ab
N
o
N
o
N
o
N
o
O
th
er
H
yd
ro
xy
ch
lo
ro
q
ui
ne
, 
su
lfa
sa
la
zi
ne
S
ul
fa
sa
la
zi
ne
—
p
ar
tia
l 
re
sp
on
se
S
ul
fa
sa
la
zi
ne
, 
hy
d
ro
xy
ch
lo
ro
q
ui
ne
—
p
ar
tia
l r
es
p
on
se
A
C
PA
, a
nt
ic
itr
ul
lin
at
ed
 p
ro
te
in
 a
nt
ib
od
y;
 A
N
A
, a
nt
in
uc
le
ar
 a
nt
ib
od
y;
 A
N
C
A
, a
nt
in
eu
tr
op
hi
l c
yt
op
la
sm
ic
 a
nt
ib
od
y;
 N
il,
 m
ea
ns
 t
ha
t 
no
 r
ar
e 
va
ria
nt
s 
w
er
e 
fo
un
d
 in
 t
he
se
 g
en
es
; R
A
, r
he
um
at
oi
d
 
ar
th
rit
is
; R
F,
 r
he
um
at
oi
d
 fa
ct
or
.
Ta
b
le
 1
 
C
on
tin
ue
d
 
group.bmj.com on November 6, 2017 - Published by http://rmdopen.bmj.com/Downloaded from 
5Savic S, et al. RMD Open 2017;3:e000550. doi:10.1136/rmdopen-2017-000550
Autoinflammatory disorders
Figure 2 Proinflammatory cytokine production from whole 
blood assay (case 2) in response to lipopolysaccharide (LPS) 
and after LPS/IL-10 combination (A,B,C). Picture of inflamed 
skin/joints, case2 (D).
dIscussIon
Herein, we report five cases of seropositive inflammatory 
arthritis, who met the European League Against Rheu-
matism/American College of Rheumatology diagnostic 
criteria for RA, but developed unusual clinical pheno-
types resembling SAID. They all had abrupt onset of syno-
vitis with associated joint erythema, excellent response to 
colchicine or anakinra, but poor response to traditional 
DMARDs. Genetic investigations showed that patients 
carried the DRB1 shared epitope, confirming their risk 
for developing RA and ACPA, and rare genetic variants 
associated with SAID.
There is only one previous report of concurrent CAPS 
and RA with a confirmed NLRP3 mutation.5 In our case 
we have also demonstrated enhanced IL-1ß release in 
response to LPS stimulation, which is typically associated 
with pathogenic gain-of-function NLRP3 mutations. The 
NLRP3 inflammasome, which is critical for release of 
active IL-1ß, has been linked to the pathogenesis of RA. 
The synovial expression of NLRP3 has positive correlation 
with the clinical and radiological arthritis scores in the 
collagen-induced model of arthritis.6 In human studies 
the genetic variation in NLRP3 inflammasome compo-
nents as well as NLRP3 inflammasome activity have been 
shown to influence the susceptibility and severity of RA, 
and response to therapy.7–9
In case 2, two sequence variants in MEFV (pyrin) were 
found. R202Q is a frequent polymorphism, however Q97* 
is probably pathogenic according to the Infevers databse10 
and associated with familial Mediterranean fever (FMF), 
a prototypical SAID known to respond to colchicine. A 
role for pyrin in pathogenesis of RA has recently been 
implied by a study showing that 14-3-3 protein, which is 
important in controlling the pyrin inflammasome acti-
vation,11 is detectable in sera of patients who later went 
onto develop seropositive RA.12 Therefore, two biological 
pathways that are intimately involved with processing of 
IL-1, a proinflammatory cytokine that defines the SAID 
field, also appear to have a role in the pathogenesis of RA. 
The IL-1β itself secreted by monocytes and macrophages 
have been shown to induce and amplify the inflamma-
tory processes in the affected joints of patients with RA.13 
Although anti-IL-1 blockade in RA has been inferior to 
anti-TNF/anti-IL-6, there is a subgroup of patients with 
RA with favourable response to anakinra. A study iden-
tified that higher disease severity, no or low dose steroid 
use, and concomitant diabetes were predictive of a 
response to anakinra.2 The authors therefore speculated 
that there might be two distinct groups of patients with 
RA, one with a more autoimmune phenotype associated 
with response to steroids and another with autoinflamma-
tory characteristics defined by poor response to steroids 
but positive response to anakinra.
Cases 3 and 4 had variants in NOD2. Mutations in 
this gene are classically associated with Crohn’s disease; 
however neither patient had any evidence of inflam-
matory bowel disease. There is some evidence that this 
gene is activated in RA. For example, NOD2 was shown 
to be expressed in fibroblasts and synovium of patients 
with RA particularly at sites of invasion into the artic-
ular cartilage.14 Similarly, higher levels of NOD2 mRNA 
expression in PBMCs has been observed in patients with 
RA when compared with patients with osteoarthritis.15 
However, cases 3 and 4 both had the alleles coding for a 
frequent polymorphism generally believed to be loss-of-
function resulting in reduced nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-kB) activation 
and lower inflammatory burden.16 The diagnosis of 
SAID in these cases was made on clinical grounds alone. 
Explanation for the clinical picture in these patients is 
therefore unclear, perhaps because of to tissue-specific 
genotype-phenotype associations.
Although genotyping was normal in case 5, clinically 
she had features of SAID and a most impressive response 
to colchicine. Recently myeloid restricted somatic muta-
tions in NLRP3 have been shown to cause some acquired 
cases of SAID.17 These mutations cannot be detected 
using the standard genotyping methods, which may 
explain why in this case none were detected. In summary, 
this case series highlights that certain patients with RA 
may have a strong autoinflammatory component driving 
their disease process. Such patients may have disease 
which is refractory to conventional RA treatment and 
thus require a more tailored treatment strategy. This 
personalised approach to the spectrum of patients with 
RA is an area where further research is required.
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